{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:17:33Z","timestamp":1764656253534,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejogrb.2023.05.028","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T20:56:26Z","timestamp":1685134586000},"page":"119-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Beta blockers reduce uterine fibroid incidence in hypertensive women"],"prefix":"10.1016","volume":"287","author":[{"given":"Nicole M.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim O.","family":"Nieuwenhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Hazimeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Voegtline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhuchitra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"Segars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejogrb.2023.05.028_b0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijgo.2015.04.051","article-title":"Prevalence, morbidity, and current medical management of uterine leiomyomas","volume":"131","author":"Drayer","year":"2015","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.ejogrb.2023.05.028_b0010","unstructured":"Baird DD, Dunson Db Fau - Hill MC, Hill Mc Fau - Cousins D, Cousins D Fau - Schectman JM, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. (0002-9378 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0015","unstructured":"Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D, Vollenhoven B. Uterine fibroids. (2056-676X (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0020","unstructured":"Marsh EE, Al-Hendy A, Kappus D, Galitsky A, Stewart EA, Kerolous M. Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women. (1931-843X (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0025","unstructured":"Cardozo ER, Clark Ad Fau - Banks NK, Banks Nk Fau - Henne MB, Henne Mb Fau - Stegmann BJ, Stegmann Bj Fau - Segars JH, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. (1097-6868 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0030","unstructured":"Hartmann KE, Birnbaum H Fau - Ben-Hamadi R, Ben-Hamadi R Fau - Wu EQ, Wu Eq Fau - Farrell MH, Farrell Mh Fau - Spalding J, Spalding J Fau - Stang P, et al. Annual costs associated with diagnosis of uterine leiomyomata. (0029-7844 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0035","unstructured":"Islam MS, Protic O Fau - Giannubilo SR, Giannubilo Sr Fau - Toti P, Toti P Fau - Tranquilli AL, Tranquilli Al Fau - Petraglia F, Petraglia F Fau - Castellucci M, et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. (1945-7197 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0040","unstructured":"Carlson KJ, Miller Ba Fau - Fowler FJ, Jr., Fowler FJ, Jr. The Maine Women's Health Study: II. Outcomes of nonsurgical management of leiomyomas, abnormal bleeding, and chronic pelvic pain. (0029-7844 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0045","unstructured":"Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. (0029-7844 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0050","unstructured":"Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. (1095-9203 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0055","unstructured":"Patel A, Malik M, Britten J, Cox J, Catherino WH. Alternative therapies in management of leiomyomas. (1556-5653 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0060","unstructured":"Ong HT. Beta blockers in hypertension and cardiovascular disease. (1756-1833 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0065","unstructured":"Cole SW, Arevalo Jm Fau - Takahashi R, Takahashi R Fau - Sloan EK, Sloan Ek Fau - Lutgendorf SK, Lutgendorf Sk Fau - Sood AK, Sood Ak Fau - Sheridan JF, et al. Computational identification of gene-social environment interaction at the human IL6 locus. (1091-6490 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0070","unstructured":"Shahzad MM, Arevalo Jm Fau - Armaiz-Pena GN, Armaiz-Pena Gn Fau - Lu C, Lu C Fau - Stone RL, Stone Rl Fau - Moreno-Smith M, Moreno-Smith M Fau - Nishimura M, et al. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. (1083-351X (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0075","unstructured":"Thaker PH, Han Ly Fau - Kamat AA, Kamat Aa Fau - Arevalo JM, Arevalo Jm Fau - Takahashi R, Takahashi R Fau - Lu C, Lu C Fau - Jennings NB, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. (1078-8956 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0080","unstructured":"Chakroborty D, Sarkar C Fau - Basu B, Basu B Fau - Dasgupta PS, Dasgupta Ps Fau - Basu S, Basu S. Catecholamines regulate tumor angiogenesis. (1538-7445 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0085","unstructured":"Entschladen F, Drell Tl 4th Fau - Lang K, Lang K Fau - Joseph J, Joseph J Fau - Zaenker KS, Zaenker KS. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. (1470-2045 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0090","unstructured":"Sood AK, Bhatty R Fau - Kamat AA, Kamat Aa Fau - Landen CN, Landen Cn Fau - Han L, Han L Fau - Thaker PH, Thaker Ph Fau - Li Y, et al. Stress hormone-mediated invasion of ovarian cancer cells. (1078-0432 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0095","doi-asserted-by":"crossref","unstructured":"Peixoto R, Pereira ML, Oliveira M. Beta-Blockers and Cancer: Where Are We? LID - 10.3390\/ph13060105 [doi] LID - 105. (1424-8247 (Print)).","DOI":"10.3390\/ph13060105"},{"key":"10.1016\/j.ejogrb.2023.05.028_b0100","unstructured":"Melhem-Bertrandt A, Chavez-Macgregor M Fau - Lei X, Lei X Fau - Brown EN, Brown En Fau - Lee RT, Lee Rt Fau - Meric-Bernstam F, Meric-Bernstam F Fau - Sood AK, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. (1527-7755 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0105","unstructured":"Fitzpatrick AL, Daling Jr Fau - Furberg CD, Furberg Cd Fau - Kronmal RA, Kronmal Ra Fau - Weissfeld JL, Weissfeld JL. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. (1047-2797 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0110","unstructured":"Perron L, Bairati I Fau - Harel F, Harel F Fau - Meyer F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). (0957-5243 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0115","unstructured":"Zhang D, Ma Q Fau - Shen S, Shen S Fau - Hu H, Hu H. Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell. (1536-4828 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0120","unstructured":"Udumyan R, Montgomery S, Fang F, Almroth H, Valdimarsdottir U, Ekbom A, et al. Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma. (1538-7445 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0125","unstructured":"Wang F, Liu H, Xu R, Wang P, Tang F, Zhang X, et al. Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells. (1791-3004 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0130","unstructured":"Borsari R, Bozzini N Fau - Junqueira CR, Junqueira Cr Fau - Soares JM, Jr., Soares Jm Jr Fau - Hil\u00e1rio SG, Hil\u00e1rio Sg Fau - Baracat EC, Baracat EC. Genic expression of the uterine leiomyoma in reproductive-aged women after treatment with goserelin. (1556-5653 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0135","unstructured":"Sliwi\u0144ski L, Folwarczna J Fau - Pytlik M, Pytlik M Fau - Cegie\u0142a U, Cegie\u0142a U Fau - Nowi\u0144ska B, Nowi\u0144ska B Fau - Trzeciak H, Trzeciak H Fau - Trzeciak HI, et al. Do effects of propranolol on the skeletal system depend on the estrogen status? (2299-5684 (Electronic))."},{"issue":"3","key":"10.1016\/j.ejogrb.2023.05.028_b0140","doi-asserted-by":"crossref","DOI":"10.1007\/s00395-017-0617-2","article-title":"Sex-difference in expression and function of beta-adrenoceptors in macrovessels: role of the endothelium","volume":"112","author":"Al-Gburi","year":"2017","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.ejogrb.2023.05.028_b0145","unstructured":"Hajagos-Toth J Fau - Bota J, Bota J Fau - Ducza E, Ducza E Fau - Csanyi A, Csanyi A Fau - Tiszai Z, Tiszai Z Fau - Borsodi A, Borsodi A Fau - Samavati R, et al. The effects of estrogen on the \u03b12-adrenergic receptor subtypes in rat uterine function in late pregnancy in vitro. (1332-8166 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0150","unstructured":"Lee TK, Cho Hl Fau - Kim DI, Kim Di Fau - Lee YC, Lee Yc Fau - Kim CH, Kim CH. Scutellaria barbata D. Don induces c-fos gene expression in human uterine leiomyomal cells by activating beta2-adrenergic receptors. (1048-891X (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0155","unstructured":"Jack D Fau - Poynter D, Poynter D Fau - Spurling NW, Spurling NW. Beta-adrenoceptor stimulants and mesovarian leiomyomas in the rat. (0300-483X (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0160","unstructured":"Gibson JP, Sells Dm Fau - Cheng HC, Cheng Hc Fau - Yuh L, Yuh L. Induction of uterine leiomyomas in mice by medroxalol and prevention by propranolol. (0192-6233 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0165","unstructured":"Gopinath C, Gibson WA. Mesovarian leiomyomas in the rat. (0091-6765 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0170","unstructured":"Radin RG, Rosenberg L Fau - Palmer JR, Palmer Jr Fau - Cozier YC, Cozier Yc Fau - Kumanyika SK, Kumanyika Sk Fau - Wise LA, Wise LA. Hypertension and risk of uterine leiomyomata in US black women. (1460-2350 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0175","unstructured":"Takeda T, Sakata M Fau - Isobe A, Isobe A Fau - Miyake A, Miyake A Fau - Nishimoto F, Nishimoto F Fau - Ota Y, Ota Y Fau - Kamiura S, et al. Relationship between metabolic syndrome and uterine leiomyomas: a case-control study. (1423-002X (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0180","unstructured":"Luoto R, Rutanen Em Fau - Auvinen A, Auvinen A. Fibroids and hypertension. A cross-sectional study of women undergoing hysterectomy. (0024-7758 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0185","unstructured":"Silver MA, Raghuvir R Fau - Fedirko B, Fedirko B Fau - Elser D, Elser D. Systemic hypertension among women with uterine leiomyomata: potential final common pathways of target end-organ remodeling. (1524-6175 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0190","unstructured":"Haan YC, Oudman I, de Lange ME, Timmermans A, Ankum WM, van Montfrans GA, et al. Hypertension risk in Dutch women with symptomatic uterine fibroids. (1941-7225 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0195","unstructured":"Elixhauser A, Steiner C Fau - Harris DR, Harris Dr Fau - Coffey RM, Coffey RM. Comorbidity measures for use with administrative data. (0025-7079 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0200","unstructured":"Hughes AD. How do thiazide and thiazide-like diuretics lower blood pressure? (1470-3203 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0205","unstructured":"Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. (1471-0528 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0210","unstructured":"Rouget C, Bardou M Fau - Breuiller-Fouch\u00e9 M, Breuiller-Fouch\u00e9 M Fau - Loustalot C, Loustalot C Fau - Qi H, Qi H Fau - Naline E, Naline E Fau - Croci T, et al. Beta3-adrenoceptor is the predominant beta-adrenoceptor subtype in human myometrium and its expression is up-regulated in pregnancy. (0021-972X (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0215","unstructured":"Adolfsson PI, Haug I Fau - Berg G, Berg G Fau - Svensson SP, Svensson SP. Changes in beta(2)-adrenoceptor expression and in adenylyl cyclase and phosphodiesterase activity in human uterine leiomyomas. (1360-9947 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0220","unstructured":"Fischer NM, Nieuwenhuis TO, Singh B, Yenokyan G, Segars JH. Angiotensin-Converting Enzyme Inhibitors Reduce Uterine Fibroid Incidence in Hypertensive Women. (1945-7197 (Electronic))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0225","unstructured":"Blumenfeld JD, Sealey Je Fau - Mann SJ, Mann Sj Fau - Bragat A, Bragat A Fau - Marion R, Marion R Fau - Pecker MS, Pecker Ms Fau - Sotelo J, et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. (0895-7061 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0230","unstructured":"Gillum RF. Epidemiology of hypertension in African American women. (0002-8703 (Print))."},{"key":"10.1016\/j.ejogrb.2023.05.028_b0235","unstructured":"Helmer A, Slater N, Smithgall S. A Review of ACE Inhibitors and ARBs in Black Patients With Hypertension. (1542-6270 (Electronic))."}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030121152300218X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030121152300218X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T06:01:25Z","timestamp":1759557685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030121152300218X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":47,"alternative-id":["S030121152300218X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2023.05.028","relation":{},"ISSN":["0301-2115"],"issn-type":[{"type":"print","value":"0301-2115"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta blockers reduce uterine fibroid incidence in hypertensive women","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2023.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}